methyl 5-iodo-2-(propan-2-yloxy)benzoate | 193882-72-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 5-iodo-2-(propan-2-yloxy)benzoate
• 英文别名: 5-Iodo-2-isopropoxy-benzoic acid methyl ester；5-iodo-2-isopropoxybenzoic acid methyl ester；methyl 5-iodo-2-(1-methylethoxy)benzoate；methyl 5-iodo-2-propan-2-yloxybenzoate
• CAS: 193882-72-3
• 化学式: C₁₁H₁₃IO₃
• 分子量: 320.127
• InChiKey: LPJYOJMUUQBSFS-UHFFFAOYSA-N

物化性质

• 沸点：
  350.6±32.0 °C(Predicted)
• 密度：
  1.548±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 5-iodo-2-(propan-2-yloxy)benzoate 在 sodium hydroxide 、 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 6.0h， 生成 5-iodo-2-(1-methylethoxy)-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide
  参考文献：
  名称：

  Synthesis and 5-HT-3 receptor binding activity of 5-[125I]iodo-2,3-dimethoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide and its 5-halogen-2-alkoxyl homologues

  摘要：

  (S)-5-Iodo-2,3-dimethoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide (MIZAC) was prepared from 5-iodo-2,3-dimethoxybenzoyl chloride and (S)-3-aminoquinuclidine. [I-125]Iodode-stannylation of its corresponding 5-tri-n-butyltin derivative gave [I-125]-MIZAC at 1800 Ci/mmol. Binding of [I-125]-MIZAC in rat entorhinal cortex revealed a K-D of 1.37 +/- 0.21 nM. A series of racemic 2-O-alkyl derivatives of MIZAC were prepared and 5-HT-3 receptor affinities were determined by inhibition of [I-125]-MIZAC binding. Optimal affinity for the receptor was obtained with small, electron-withdrawing substituents in the aromatic 5-position and with bulky substituents in the 3-position. [I-125]-MIZAC is a selective radioligand useful for in vitro identification of the 5-HT-3 receptor.

  DOI：

  10.1016/s0223-5234(97)81676-5
• 作为产物：
  描述：

  5-碘水杨酸甲酯 、 2-溴丙烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以93%的产率得到methyl 5-iodo-2-(propan-2-yloxy)benzoate
  参考文献：
  名称：

  Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators

  摘要：

  Identification and synthesis of novel 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as glucokinase activators are described. Removal of an aniline structure of the prototype lead (2a) and incorporation of an alkoxy or phenoxy substituent led to the identification of 3-Isopropoxy-5-[4-(methylsulfonyl) phenoxy]-N(4- methyl-1,3-thiazol-2-yl) benzamide (27e) as a novel, potent, and orally bioavailable GK activator. Rat oral glucose tolerance test indicated that 27e exhibited a glucose-lowering effect after 10 mg/kg oral administration. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.02.038

文献信息

• 2,3,4,9-Tetrahydro-1H-carbazoles
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1975159A1

  公开（公告）日：2008-10-01

  The present invention relates to 2,3,4,9-tetrahydro-1 H-carbazoles of the general formula I, in which Q, X, W, R1, R2, R3, R4 and R5 have the meaning as defined in the description. The compounds according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis.

  本发明涉及通式I的2,3,4,9-四氢-1H-咔唑， 其中Q、X、W、R1、R2、R3、R4和R5的含义如描述中所定义。 根据本发明的化合物是有效的FSH拮抗剂，可用于男性或女性的生育控制，或用于骨质疏松症的预防和/或治疗。
• Arylmethylene substituted N-acyl-beta-amino alcohols
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP2018859A1

  公开（公告）日：2009-01-28

  The present invention relates to arylmethylene substituted N-Acyl-β-amino alcohols of the formula I in which Y is selected from the aryl or heteroaryl groups: and R1, R2, R3, R4, R5, Q, X and W have the meaning as defined in the description. The compounds according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis.

  本发明涉及式I的芳基亚甲基取代的N-酰基-β-氨基醇 其中 Y 从芳基或杂芳基中选择: 和 R1、R2、R3、R4、R5、Q、X和W的含义如描述中所定义。 根据本发明的化合物是有效的FSH拮抗剂，例如可用于男性或女性的生育控制，或用于骨质疏松症的预防和/或治疗。
• Cyanomethyl substituted N-Acyl Tryptamines
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP2020404A1

  公开（公告）日：2009-02-04

  The present invention relates to cyanomethyl substituted N-acyl tryptamines of the formula I in which R1, R2, R3, R4, R5, Q, X and W have the meaning as defined in the description. The compounds according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis.

  本发明涉及具有以下结构的氰甲基取代的N-酰基色胺化合物，其中R1、R2、R3、R4、R5、Q、X和W的含义如描述中所定义。根据本发明的化合物是有效的FSH拮抗剂，可用于男性或女性的生育控制，或用于骨质疏松症的预防和/或治疗。
• 1,2-Diarylacetylene Derivatives of Acyltryptophanols
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1932831A1

  公开（公告）日：2008-06-18

  The present invention relates to acyltryptophanols of the general formula I, in which Q, W, R1, R2, R3, R4, R5, R6, R7 and R8 have the meaning as defined in the description. The compounds according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis.

  本发明涉及通式I的酰基色氨酸醇，其中Q、W、R1、R2、R3、R4、R5、R6、R7和R8的含义如描述中所定义。根据本发明的化合物是有效的FSH拮抗剂，可用于例如男性或女性的生育控制，或用于骨质疏松症的预防和/或治疗。
• Arymethylen substituted N-Acyl-gamma-aminoalcohols
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1985612A1

  公开（公告）日：2008-10-29

  The present invention relates to arylmethylen substituted N-acyl-γ-aminoalcohols of the general formula I in which Q, X, W, R1, R2, R3, R4 and R5 have the meaning as defined in the description. The compounds according to the invention are effective FSH modulators and can be used for example for fertility regulation in men or in women.

  本发明涉及一般式I中的芳基甲基取代的N-酰基-γ-氨基醇，其中Q、X、W、R1、R2、R3、R4和R5的含义如描述中所定义。本发明的化合物是有效的FSH调节剂，例如可用于男性或女性的生育调节。